Zacks Investment Research
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
AstraZeneca announced FDA approval of Ultomiris (ravulizumab) for reducing proteinuria in adults with primary IgAN at risk of disease progression. This marks the drug's fifth U.S. indication and makes it the first C5 complement inhibitor approved for this use. Ultomiris sales grew 14% to $2.58 billion in H1 2026, though the company faces competition from Calliditas, Novartis, and Travere in the IgAN market.
